{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T14:45:32Z","timestamp":1794408332935,"version":"4.9.0"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-22034-x","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T12:45:54Z","timestamp":1761914754000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of (Z)-endoxifen as a potential therapy for glioblastoma multiforme through computational and experimental analyses"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1155-2551","authenticated-orcid":false,"given":"Anastasia","family":"Shneyderman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7760-4582","authenticated-orcid":false,"given":"Sandra S.","family":"Hammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5742-829X","authenticated-orcid":false,"given":"H. Lawrence","family":"Remmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1006-5944","authenticated-orcid":false,"given":"Alexander","family":"Veviorskiy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9208-9131","authenticated-orcid":false,"given":"Khadija M.","family":"Alawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1065-4206","authenticated-orcid":false,"given":"Alina","family":"Ustiugova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1866-4318","authenticated-orcid":false,"given":"Mikhail","family":"Korzinkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7067-8966","authenticated-orcid":false,"given":"Alex","family":"Zhavoronkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0363-7651","authenticated-orcid":false,"given":"Steven C.","family":"Quay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"22034_CR1","doi-asserted-by":"publisher","first-page":"11622","DOI":"10.1038\/s41598-020-68011-4","volume":"10","author":"MTC Poon","year":"2020","unstructured":"Poon, M. T. C., Sudlow, C. L. M., Figueroa, J. D. & Brennan, P. M. Longer-term (\u2265 2 years) survival in patients with glioblastoma in population-based studies pre- and post-2005: A systematic review and meta-analysis. Sci. Rep. 10, 11622 (2020).","journal-title":"Sci. Rep."},{"key":"22034_CR2","first-page":"550","volume":"17","author":"A Veviorskiy","year":"2025","unstructured":"Veviorskiy, A. et al. Variability in radiotherapy outcomes across cancer types: A comparative study of glioblastoma multiforme and low-grade gliomas. Aging (Albany NY) 17, 550\u2013562 (2025).","journal-title":"Aging (Albany NY)"},{"key":"22034_CR3","doi-asserted-by":"publisher","first-page":"3994","DOI":"10.3390\/curroncol31070296","volume":"31","author":"M Jezierza\u0144ski","year":"2024","unstructured":"Jezierza\u0144ski, M. et al. Temozolomide (TMZ) in the treatment of glioblastoma multiforme\u2014A literature review and clinical outcomes. Curr. Oncol. 31, 3994\u20134002 (2024).","journal-title":"Curr. Oncol."},{"key":"22034_CR4","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.3390\/brainsci13111536","volume":"13","author":"RS Angom","year":"2023","unstructured":"Angom, R. S., Nakka, N. M. R. & Bhattacharya, S. Advances in glioblastoma therapy: An update on current approaches. Brain Sci. 13, 1536 (2023).","journal-title":"Brain Sci."},{"key":"22034_CR5","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1038\/s41587-019-0224-x","volume":"37","author":"A Zhavoronkov","year":"2019","unstructured":"Zhavoronkov, A. et al. Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nat. Biotechnol. 37, 1038\u20131040 (2019).","journal-title":"Nat. Biotechnol."},{"key":"22034_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.914017","volume":"14","author":"FW Pun","year":"2022","unstructured":"Pun, F. W. et al. Identification of therapeutic targets for amyotrophic lateral sclerosis using PandaOmics\u2014An AI-enabled biological target discovery platform. Front. Aging Neurosci. 14, 914017 (2022).","journal-title":"Front. Aging Neurosci."},{"key":"22034_CR7","first-page":"2863","volume":"15","author":"A Olsen","year":"2023","unstructured":"Olsen, A. et al. Identification of dual-purpose therapeutic targets implicated in aging and glioblastoma multiforme using PandaOmics\u2014An AI-enabled biological target discovery platform. Aging (Albany NY) 15, 2863\u20132876 (2023).","journal-title":"Aging (Albany NY)"},{"key":"22034_CR8","doi-asserted-by":"publisher","first-page":"2406565","DOI":"10.1002\/advs.202406565","volume":"12","author":"BHM Liu","year":"2024","unstructured":"Liu, B. H. M. et al. Utilizing AI for the identification and validation of novel therapeutic targets and repurposed drugs for endometriosis. Adv. Sci. (Weinh.) 12, 2406565. https:\/\/doi.org\/10.1002\/advs.202406565 (2024).","journal-title":"Adv. Sci. (Weinh.)"},{"key":"22034_CR9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41514-024-00163-3","volume":"10","author":"D Sidorenko","year":"2024","unstructured":"Sidorenko, D. et al. Precious2GPT: The combination of multiomics pretrained transformer and conditional diffusion for artificial multi-omics multi-species multi-tissue sample generation. NPJ Aging 10, 37 (2024).","journal-title":"NPJ Aging"},{"key":"22034_CR10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1159\/000534827","volume":"185","author":"HM Liu","year":"2024","unstructured":"Liu, H. M. et al. Applying artificial intelligence to identify common targets for treatment of asthma, eczema, and food allergy. Int. Arch. Allergy Immunol. 185, 99\u2013110 (2024).","journal-title":"Int. Arch. Allergy Immunol."},{"key":"22034_CR11","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41587-024-02143-0","volume":"43","author":"F Ren","year":"2024","unstructured":"Ren, F. et al. A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models. Nat. Biotechnol. 43, 63\u201375. https:\/\/doi.org\/10.1038\/s41587-024-02143-0 (2024).","journal-title":"Nat. Biotechnol."},{"key":"22034_CR12","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s43588-024-00679-4","volume":"4","author":"M Yu","year":"2024","unstructured":"Yu, M. et al. Deep learning large-scale drug discovery and repurposing. Nat. Comput. Sci. 4, 600\u2013614 (2024).","journal-title":"Nat. Comput. Sci."},{"key":"22034_CR13","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s41573-025-01164-x","volume":"24","author":"Z Tanoli","year":"2025","unstructured":"Tanoli, Z. et al. Computational drug repurposing: approaches, evaluation of in silico resources and case studies. Nat. Rev. Drug Discov. 24, 521\u2013542. https:\/\/doi.org\/10.1038\/s41573-025-01164-x (2025).","journal-title":"Nat. Rev. Drug Discov."},{"key":"22034_CR14","first-page":"e2411325","volume":"12","author":"Z Wan","year":"2025","unstructured":"Wan, Z. et al. Applications of artificial intelligence in drug repurposing. Adv. Sci. (Weinh.) 12, e2411325 (2025).","journal-title":"Adv. Sci. (Weinh.)"},{"key":"22034_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s11030-025-11162-1","author":"D Kaur","year":"2025","unstructured":"Kaur, D., Chopra, M. & Saluja, D. Exploiting the Achilles\u2019 heel of cancer through a structure-based drug-repurposing approach and experimental validation of top drugs using the TRAP assay. Mol. Divers. https:\/\/doi.org\/10.1007\/s11030-025-11162-1 (2025).","journal-title":"Mol. Divers."},{"key":"22034_CR16","doi-asserted-by":"publisher","first-page":"bqab191","DOI":"10.1210\/endocr\/bqab191","volume":"162","author":"S Jayaraman","year":"2021","unstructured":"Jayaraman, S., Reid, J. M., Hawse, J. R. & Goetz, M. P. Endoxifen, an estrogen receptor targeted therapy: From bench to bedside. Endocrinology 162, bqab191 (2021).","journal-title":"Endocrinology"},{"key":"22034_CR17","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/clpt.2011.27","volume":"89","author":"TE M\u00fcrdter","year":"2011","unstructured":"M\u00fcrdter, T. E. et al. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin. Pharmacol. Ther. 89, 708\u2013717 (2011).","journal-title":"Clin. Pharmacol. Ther."},{"key":"22034_CR18","doi-asserted-by":"publisher","first-page":"PD2-03","DOI":"10.1158\/1538-7445.SABCS15-PD2-03","volume":"76","author":"MP Goetz","year":"2016","unstructured":"Goetz, M. P. et al. Abstract PD2-03: Final results of a first-in-human phase I study of the tamoxifen (TAM) metabolite, Z-Endoxifen hydrochloride (Z-Endx) in women with aromatase inhibitor (AI) refractory metastatic breast cancer (MBC) (NCT01327781). Cancer Res. 76, PD2-03 (2016).","journal-title":"Cancer Res."},{"key":"22034_CR19","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1200\/JCO.2017.73.3246","volume":"35","author":"MP Goetz","year":"2017","unstructured":"Goetz, M. P. et al. First-in-human phase i study of the tamoxifen metabolite Z-endoxifen in women with endocrine-refractory metastatic breast cancer. J. Clin. Oncol. 35, 3391\u20133400 (2017).","journal-title":"J. Clin. Oncol."},{"key":"22034_CR20","doi-asserted-by":"publisher","first-page":"268","DOI":"10.18632\/oncotarget.27887","volume":"12","author":"N Takebe","year":"2021","unstructured":"Takebe, N. et al. Phase 1 study of Z-endoxifen in patients with advanced gynecologic, desmoid, and hormone receptor-positive solid tumors. Oncotarget 12, 268\u2013277 (2021).","journal-title":"Oncotarget"},{"key":"22034_CR21","doi-asserted-by":"publisher","first-page":"CT205","DOI":"10.1158\/1538-7445.AM2024-CT205","volume":"84","author":"MP Goetz","year":"2024","unstructured":"Goetz, M. P. et al. Abstract CT205: Neoadjuvant (Z)-endoxifen in premenopausal ER+, HER2- breast cancer: Evaluation of the first pharmacokinetic cohort of the EVANGELINE trial. Cancer Res. 84, CT205 (2024).","journal-title":"Cancer Res."},{"key":"22034_CR22","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/cts.12407","volume":"9","author":"A Ahmad","year":"2016","unstructured":"Ahmad, A. et al. Endoxifen, a new treatment option for mania: A double-blind, active-controlled trial demonstrates the antimanic efficacy of endoxifen. Clin. Transl. Sci. 9, 252\u2013259 (2016).","journal-title":"Clin. Transl. Sci."},{"key":"22034_CR23","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/bdi.13041","volume":"23","author":"A Ahmad","year":"2021","unstructured":"Ahmad, A. et al. Endoxifen: A new, protein kinase C inhibitor to treat acute and mixed mania associated with bipolar I disorder. Bipolar Disord. 23, 595\u2013603 (2021).","journal-title":"Bipolar Disord."},{"key":"22034_CR24","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1002\/cncr.20981","volume":"103","author":"J Melnikow","year":"2005","unstructured":"Melnikow, J. et al. Preferences of women evaluating risks of tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction. Cancer 103, 1996\u20132005 (2005).","journal-title":"Cancer"},{"key":"22034_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0054613","volume":"8","author":"JR Hawse","year":"2013","unstructured":"Hawse, J. R. et al. Endoxifen\u2019s molecular mechanisms of action are concentration dependent and different than that of other anti-estrogens. PLoS ONE 8, e54613 (2013).","journal-title":"PLoS ONE"},{"key":"22034_CR26","doi-asserted-by":"publisher","first-page":"P2-24-03","DOI":"10.1158\/1538-7445.SABCS22-P2-24-03","volume":"83","author":"SS Bhattacharya","year":"2023","unstructured":"Bhattacharya, S. S. et al. Abstract P2\u201324-03: Z-Endoxifen allosterically inhibits PKC\u03b2I and its paradoxical membrane translocation. Cancer Res. 83, P2-24\u201303 (2023).","journal-title":"Cancer Res."},{"key":"22034_CR27","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41523-023-00606-2","volume":"9","author":"S Jayaraman","year":"2023","unstructured":"Jayaraman, S. et al. Endoxifen downregulates AKT phosphorylation through protein kinase C beta 1 inhibition in ER\u03b1+ breast cancer. NPJ Breast Cancer 9, 101 (2023).","journal-title":"NPJ Breast Cancer"},{"key":"22034_CR28","doi-asserted-by":"publisher","first-page":"R27","DOI":"10.1186\/bcr2844","volume":"13","author":"X Wu","year":"2011","unstructured":"Wu, X. et al. Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen. Breast Cancer Res. 13, R27 (2011).","journal-title":"Breast Cancer Res."},{"key":"22034_CR29","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10549-011-1699-4","volume":"133","author":"WJ Lu","year":"2012","unstructured":"Lu, W. J. et al. The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents. Breast Cancer Res. Treat. 133, 99\u2013109 (2012).","journal-title":"Breast Cancer Res. Treat."},{"key":"22034_CR30","doi-asserted-by":"publisher","first-page":"D991","DOI":"10.1093\/nar\/gks1193","volume":"41","author":"T Barrett","year":"2013","unstructured":"Barrett, T. et al. NCBI GEO: archive for functional genomics data sets\u2014Update. Nucleic Acids Res. 41, D991\u2013D995 (2013).","journal-title":"Nucleic Acids Res."},{"key":"22034_CR31","doi-asserted-by":"publisher","first-page":"D747","DOI":"10.1093\/nar\/gkl995","volume":"35","author":"H Parkinson","year":"2007","unstructured":"Parkinson, H. et al. ArrayExpress\u2014A public database of microarray experiments and gene expression profiles. Nucleic Acids Res. 35, D747\u2013D750 (2007).","journal-title":"Nucleic Acids Res."},{"key":"22034_CR32","doi-asserted-by":"publisher","first-page":"D543","DOI":"10.1093\/nar\/gkab1038","volume":"50","author":"Y Perez-Riverol","year":"2022","unstructured":"Perez-Riverol, Y. et al. The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences. Nucleic Acids Res. 50, D543\u2013D552 (2022).","journal-title":"Nucleic Acids Res."},{"key":"22034_CR33","doi-asserted-by":"publisher","first-page":"3961","DOI":"10.1021\/acs.jcim.3c01619","volume":"64","author":"P Kamya","year":"2024","unstructured":"Kamya, P. et al. PandaOmics: An AI-Driven platform for therapeutic target and biomarker discovery. J. Chem. Inf. Model. 64, 3961\u20133969. https:\/\/doi.org\/10.1021\/acs.jcim.3c01619 (2024).","journal-title":"J. Chem. Inf. Model."},{"key":"22034_CR34","doi-asserted-by":"publisher","first-page":"btac57","DOI":"10.1093\/bioinformatics\/btac757","volume":"39","author":"Z Fang","year":"2023","unstructured":"Fang, Z., Liu, X. & Peltz, G. GSEApy: A comprehensive package for performing gene set enrichment analysis in Python. Bioinformatics 39, btac57 (2023).","journal-title":"Bioinformatics"},{"key":"22034_CR35","doi-asserted-by":"publisher","first-page":"9293","DOI":"10.18632\/aging.205055","volume":"15","author":"D Zagirova","year":"2023","unstructured":"Zagirova, D. et al. Biomedical generative pre-trained based transformer language model for age-related disease target discovery. Aging (Albany NY) 15, 9293\u20139309 (2023).","journal-title":"Aging (Albany NY)"},{"key":"22034_CR36","doi-asserted-by":"publisher","first-page":"W212","DOI":"10.1093\/nar\/gkz446","volume":"47","author":"AB Keenan","year":"2019","unstructured":"Keenan, A. B. et al. ChEA3: Transcription factor enrichment analysis by orthogonal omics integration. Nucleic Acids Res. 47, W212\u2013W224 (2019).","journal-title":"Nucleic Acids Res."},{"key":"22034_CR37","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.celrep.2017.10.030","volume":"21","author":"S Darmanis","year":"2017","unstructured":"Darmanis, S. et al. Single-cell RNA-seq analysis of infiltrating neoplastic cells at the migrating front of human glioblastoma. Cell Rep. 21, 1399\u20131410 (2017).","journal-title":"Cell Rep."},{"key":"22034_CR38","doi-asserted-by":"publisher","first-page":"eabm6340","DOI":"10.1126\/sciadv.abm6340","volume":"8","author":"Y Hu","year":"2022","unstructured":"Hu, Y. et al. Neural network learning defines glioblastoma features to be of neural crest perivascular or radial glia lineages. Sci. Adv. 8, eabm6340 (2022).","journal-title":"Sci. Adv."},{"key":"22034_CR39","unstructured":"The Cancer Genome Atlas Program (TCGA). https:\/\/www.cancer.gov\/tcga (2022)."},{"key":"22034_CR40","doi-asserted-by":"publisher","DOI":"10.1101\/2024.10.02.616224","author":"HL Remmel","year":"2024","unstructured":"Remmel, H. L. et al. Comparative analysis of endoxifen, tamoxifen and fulvestrant: A bioinformatics approach to uncover mechanisms of action in breast cancer. bioRxiv https:\/\/doi.org\/10.1101\/2024.10.02.616224 (2024).","journal-title":"bioRxiv"},{"key":"22034_CR41","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1215\/S1522851705000311","volume":"8","author":"HI Robins","year":"2006","unstructured":"Robins, H. I. et al. Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-0021. Neuro. Oncol. 8, 47\u201352 (2006).","journal-title":"Neuro. Oncol."},{"key":"22034_CR42","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1093\/neuonc\/noq146","volume":"13","author":"SJ Byer","year":"2011","unstructured":"Byer, S. J. et al. Tamoxifen inhibits malignant peripheral nerve sheath tumor growth in an estrogen receptor-independent manner. Neuro. Oncol. 13, 28\u201341 (2011).","journal-title":"Neuro. Oncol."},{"key":"22034_CR43","first-page":"3383","volume":"33","author":"A DI Cristofori","year":"2013","unstructured":"DI Cristofori, A. et al. Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma. Anticancer Res. 33, 3383\u20133389 (2013).","journal-title":"Anticancer Res."},{"key":"22034_CR44","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1093\/jnen\/nlw071","volume":"75","author":"CD Graham","year":"2016","unstructured":"Graham, C. D. et al. Tamoxifen induces cytotoxic autophagy in glioblastoma. J. Neuropathol. Exp. Neurol. 75, 946 (2016).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"22034_CR45","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/S0959-8049(99)00003-9","volume":"35","author":"AB da Rocha","year":"1999","unstructured":"da Rocha, A. B. et al. Tamoxifen inhibits particulate-associated protein kinase C activity, and sensitises cultured human glioblastoma cells not to etoposide but to gamma-radiation and BCNU. Eur. J. Cancer 35, 833\u2013839 (1999).","journal-title":"Eur. J. Cancer"},{"key":"22034_CR46","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s41984-024-00294-5","volume":"39","author":"M Sabouri","year":"2024","unstructured":"Sabouri, M., Dogonchi, A. F., Shafiei, M. & Tehrani, D. S. Survival rate of patient with glioblastoma: a population-based study. Egypt. J. Neurosurg. 39, 42 (2024).","journal-title":"Egypt. J. Neurosurg."},{"key":"22034_CR47","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.3390\/ijms25063217","volume":"25","author":"AS Karve","year":"2024","unstructured":"Karve, A. S. et al. A review of approaches to potentiate the activity of temozolomide against glioblastoma to overcome resistance. Int. J. Mol. Sci. 25, 3217 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"22034_CR48","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s12031-015-0602-x","volume":"57","author":"M Harmalkar","year":"2015","unstructured":"Harmalkar, M., Upraity, S., Kazi, S. & Shirsat, N. V. Tamoxifen-induced cell death of malignant glioma cells is brought about by oxidative-stress-mediated alterations in the expression of BCL2 family members and is enhanced on miR-21 inhibition. J. Mol. Neurosci. 57, 197\u2013202 (2015).","journal-title":"J. Mol. Neurosci."},{"key":"22034_CR49","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/cas.13868","volume":"110","author":"C Qu","year":"2019","unstructured":"Qu, C. et al. Estrogen receptor variant ER-\u03b136 promotes tamoxifen agonist activity in glioblastoma cells. Cancer Sci. 110, 221 (2019).","journal-title":"Cancer Sci."},{"key":"22034_CR50","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/CAD.0000000000000197","volume":"26","author":"W He","year":"2015","unstructured":"He, W., Liu, R., Yang, S.-H. & Yuan, F. Chemotherapeutic effect of tamoxifen on temozolomide-resistant gliomas. Anticancer Drugs 26, 293\u2013300 (2015).","journal-title":"Anticancer Drugs"},{"key":"22034_CR51","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3389\/fncel.2016.00243","volume":"10","author":"M Valny","year":"2016","unstructured":"Valny, M., Honsa, P., Kirdajova, D., Kamenik, Z. & Anderova, M. Tamoxifen in the mouse brain: Implications for fate-mapping studies using the tamoxifen-inducible cre-loxP system. Front. Cell. Neurosci. 10, 243 (2016).","journal-title":"Front. Cell. Neurosci."},{"key":"22034_CR52","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13058-020-01286-7","volume":"22","author":"S Jayaraman","year":"2020","unstructured":"Jayaraman, S. et al. Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer. Breast Cancer Res. 22, 51 (2020).","journal-title":"Breast Cancer Res."},{"key":"22034_CR53","doi-asserted-by":"publisher","first-page":"806","DOI":"10.3390\/biomedicines10040806","volume":"10","author":"F Torrisi","year":"2022","unstructured":"Torrisi, F. et al. The hallmarks of glioblastoma: Heterogeneity, intercellular crosstalk and molecular signature of invasiveness and progression. Biomedicines 10, 806 (2022).","journal-title":"Biomedicines"},{"key":"22034_CR54","doi-asserted-by":"publisher","first-page":"354","DOI":"10.20892\/j.issn.2095-3941.2018.0030","volume":"15","author":"AM Castro-Gamero","year":"2018","unstructured":"Castro-Gamero, A. M., Pezuk, J. A., Brassesco, M. S. & Tone, L. G. G2\/M inhibitors as pharmacotherapeutic opportunities for glioblastoma: the old, the new, and the future. Cancer Biol. Med. 15, 354\u2013374 (2018).","journal-title":"Cancer Biol. Med."},{"key":"22034_CR55","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1038\/nature07443","volume":"455","author":"H Zheng","year":"2008","unstructured":"Zheng, H. et al. p53 and Pten control neural and glioma stem\/progenitor cell renewal and differentiation. Nature 455, 1129\u20131133 (2008).","journal-title":"Nature"},{"key":"22034_CR56","doi-asserted-by":"publisher","first-page":"4632","DOI":"10.1038\/ncomms5632","volume":"5","author":"D Annibali","year":"2014","unstructured":"Annibali, D. et al. Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis. Nat. Commun. 5, 4632 (2014).","journal-title":"Nat. Commun."},{"key":"22034_CR57","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/labinvest.3780280","volume":"81","author":"AB Hui","year":"2001","unstructured":"Hui, A. B., Lo, K. W., Yin, X. L., Poon, W. S. & Ng, H. K. Detection of multiple gene amplifications in glioblastoma multiforme using array-based comparative genomic hybridization. Lab. Invest. 81, 717\u2013723 (2001).","journal-title":"Lab. Invest."},{"key":"22034_CR58","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1215\/15228517-2008-113","volume":"11","author":"JG Hodgson","year":"2009","unstructured":"Hodgson, J. G. et al. Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts. Neuro. Oncol. 11, 477\u2013487 (2009).","journal-title":"Neuro. Oncol."},{"key":"22034_CR59","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","volume":"155","author":"CW Brennan","year":"2013","unstructured":"Brennan, C. W. et al. The somatic genomic landscape of glioblastoma. Cell 155, 462\u2013477 (2013).","journal-title":"Cell"},{"key":"22034_CR60","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1093\/annonc\/mdx106","volume":"28","author":"M Touat","year":"2017","unstructured":"Touat, M., Idbaih, A., Sanson, M. & Ligon, K. L. Glioblastoma targeted therapy: Updated approaches from recent biological insights. Ann. Oncol. 28, 1457\u20131472 (2017).","journal-title":"Ann. Oncol."},{"key":"22034_CR61","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1002\/stem.521","volume":"28","author":"J Sunayama","year":"2010","unstructured":"Sunayama, J. et al. Crosstalk between the PI3K\/mTOR and MEK\/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells. Stem Cells 28, 1930\u20131939 (2010).","journal-title":"Stem Cells"},{"key":"22034_CR62","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nrclinonc.2013.10","volume":"10","author":"J Rodon","year":"2013","unstructured":"Rodon, J., Dienstmann, R., Serra, V. & Tabernero, J. Development of PI3K inhibitors: Lessons learned from early clinical trials. Nat. Rev. Clin. Oncol. 10, 143\u2013153 (2013).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"22034_CR63","doi-asserted-by":"publisher","first-page":"4899","DOI":"10.3390\/ijms22094899","volume":"22","author":"M Colardo","year":"2021","unstructured":"Colardo, M., Segatto, M. & Di Bartolomeo, S. Targeting RTK-PI3K-mTOR axis in gliomas: An update. Int. J. Mol. Sci. 22, 4899 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"22034_CR64","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/noz150","volume":"21","author":"QT Ostrom","year":"2019","unstructured":"Ostrom, Q. T. et al. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2012\u20132016. Neuro. Oncol. 21, v1\u2013v100 (2019).","journal-title":"Neuro. Oncol."},{"key":"22034_CR65","doi-asserted-by":"publisher","first-page":"932","DOI":"10.3171\/jns.2000.93.6.0932","volume":"93","author":"BP McKinley","year":"2000","unstructured":"McKinley, B. P., Michalek, A. M., Fenstermaker, R. A. & Plunkett, R. J. The impact of age and sex on the incidence of glial tumors in New York state from 1976 to 1995. J. Neurosurg. 93, 932\u2013939 (2000).","journal-title":"J. Neurosurg."},{"key":"22034_CR66","doi-asserted-by":"publisher","first-page":"2314693","DOI":"10.1155\/2020\/2314693","volume":"2020","author":"CC Castracani","year":"2020","unstructured":"Castracani, C. C. et al. Role of 17\u03b2-Estradiol on cell proliferation and mitochondrial fitness in glioblastoma cells. J. Oncol. 2020, 2314693 (2020).","journal-title":"J. Oncol."},{"key":"22034_CR67","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.3390\/cells9091930","volume":"9","author":"AM Hern\u00e1ndez-Vega","year":"2020","unstructured":"Hern\u00e1ndez-Vega, A. M. et al. Estradiol induces epithelial to mesenchymal transition of human glioblastoma cells. Cells 9, 1930 (2020).","journal-title":"Cells"},{"key":"22034_CR68","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.3892\/ol.2011.385","volume":"2","author":"N Altiok","year":"2011","unstructured":"Altiok, N., Ersoz, M. & Koyuturk, M. Estradiol induces JNK-dependent apoptosis in glioblastoma cells. Oncol. Lett. 2, 1281\u20131285 (2011).","journal-title":"Oncol. Lett."},{"key":"22034_CR69","doi-asserted-by":"publisher","first-page":"481","DOI":"10.6061\/clinics\/2016(08)12","volume":"71","author":"CB Tavares","year":"2016","unstructured":"Tavares, C. B. et al. Expression of estrogen and progesterone receptors in astrocytomas: A literature review. Clinics (Sao Paulo) 71, 481\u2013486 (2016).","journal-title":"Clinics (Sao Paulo)"},{"key":"22034_CR70","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.bbamcr.2011.11.004","volume":"1823","author":"A Gonz\u00e1lez-Arenas","year":"2012","unstructured":"Gonz\u00e1lez-Arenas, A. et al. Estradiol increases cell growth in human astrocytoma cell lines through ER\u03b1 activation and its interaction with SRC-1 and SRC-3 coactivators. Biochim. Biophys. Acta 1823, 379\u2013386 (2012).","journal-title":"Biochim. Biophys. Acta"},{"key":"22034_CR71","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41420-018-0113-y","volume":"4","author":"S Wan","year":"2018","unstructured":"Wan, S. et al. Estrogen nuclear receptors affect cell migration by altering sublocalization of AQP2 in glioma cell lines. Cell Death Discov 4, 49 (2018).","journal-title":"Cell Death Discov"},{"key":"22034_CR72","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s11060-020-03467-y","volume":"147","author":"LS H\u00f6nikl","year":"2020","unstructured":"H\u00f6nikl, L. S. et al. High expression of estrogen receptor alpha and aromatase in glial tumor cells is associated with gender-independent survival benefits in glioblastoma patients. J. Neurooncol. 147, 567\u2013575 (2020).","journal-title":"J. Neurooncol."},{"key":"22034_CR73","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1158\/1535-7163.MCT-11-0960","volume":"11","author":"GR Sareddy","year":"2012","unstructured":"Sareddy, G. R. et al. Therapeutic significance of estrogen receptor \u03b2 agonists in gliomas. Mol. Cancer Ther. 11, 1174\u20131182 (2012).","journal-title":"Mol. Cancer Ther."},{"key":"22034_CR74","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1002\/stem.3337","volume":"39","author":"GR Sareddy","year":"2021","unstructured":"Sareddy, G. R. et al. Activation of estrogen receptor beta signaling reduces stemness of glioma stem cells. Stem Cells 39, 536\u2013550 (2021).","journal-title":"Stem Cells"},{"key":"22034_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2020.153030","volume":"216","author":"H Yu","year":"2020","unstructured":"Yu, H., Zhang, D., Li, Z. & Wang, M. E2F transcription factor 8 promotes proliferation and radioresistance in glioblastoma. Pathol. Res. Pract. 216, 153030 (2020).","journal-title":"Pathol. Res. Pract."},{"key":"22034_CR76","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/cns.13295","volume":"26","author":"H Yu","year":"2020","unstructured":"Yu, H., Li, Z. & Wang, M. Expression and prognostic role of E2F transcription factors in high-grade glioma. CNS Neurosci. Ther. 26, 741\u2013753 (2020).","journal-title":"CNS Neurosci. Ther."},{"key":"22034_CR77","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.molcel.2016.11.003","volume":"65","author":"RS Blanc","year":"2017","unstructured":"Blanc, R. S. & Richard, S. Arginine methylation: The coming of age. Mol. Cell 65, 8\u201324 (2017).","journal-title":"Mol. Cell"},{"key":"22034_CR78","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1038\/s41419-022-05389-1","volume":"13","author":"Y Liao","year":"2022","unstructured":"Liao, Y. et al. PRMT3 drives glioblastoma progression by enhancing HIF1A and glycolytic metabolism. Cell Death Dis. 13, 943 (2022).","journal-title":"Cell Death Dis."},{"key":"22034_CR79","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.907120","volume":"10","author":"C Renaud-Pageot","year":"2022","unstructured":"Renaud-Pageot, C., Quivy, J.-P., Lochhead, M. & Almouzni, G. CENP-A regulation and cancer. Front. Cell Dev. Biol. 10, 907120 (2022).","journal-title":"Front. Cell Dev. Biol."},{"key":"22034_CR80","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.931222","volume":"13","author":"Y Yang","year":"2022","unstructured":"Yang, Y., Duan, M., Zha, Y. & Wu, Z. CENP-A is a potential prognostic biomarker and correlated with immune infiltration levels in glioma patients. Front. Genet. 13, 931222 (2022).","journal-title":"Front. Genet."},{"key":"22034_CR81","doi-asserted-by":"publisher","first-page":"1015221","DOI":"10.3389\/fneur.2022.1015221","volume":"13","author":"B Wang","year":"2022","unstructured":"Wang, B. et al. CENPA acts as a prognostic factor that relates to immune infiltrates in gliomas. Front. Neurol. 13, 1015221 (2022).","journal-title":"Front. Neurol."},{"key":"22034_CR82","doi-asserted-by":"publisher","first-page":"zcaa022","DOI":"10.1093\/narcan\/zcaa022","volume":"2","author":"R Dueva","year":"2020","unstructured":"Dueva, R. & Iliakis, G. Replication protein A: A multifunctional protein with roles in DNA replication, repair and beyond. NAR Cancer 2, zcaa022 (2020).","journal-title":"NAR Cancer"},{"key":"22034_CR83","first-page":"248","volume":"28","author":"T Jin","year":"2013","unstructured":"Jin, T. et al. TP53 and RPA3 gene variations were associated with risk of glioma in a Chinese Han population. Cancer Biother. Radiopharm. 28, 248\u2013253 (2013).","journal-title":"Cancer Biother. Radiopharm."},{"key":"22034_CR84","doi-asserted-by":"publisher","first-page":"80","DOI":"10.14715\/cmb\/2023.69.5.14","volume":"69","author":"L Liang","year":"2023","unstructured":"Liang, L. et al. RPA3 promotes the proliferation, migration, and invasion of gliomas by activating the PI3K-AKT-mTOR pathway. Cell. Mol. Biol. (Noisy-le-grand) 69, 80\u201386 (2023).","journal-title":"Cell. Mol. Biol. (Noisy-le-grand)"},{"key":"22034_CR85","doi-asserted-by":"publisher","first-page":"1188253","DOI":"10.3389\/fimmu.2023.1188253","volume":"14","author":"Y Feng","year":"2023","unstructured":"Feng, Y. et al. The central inflammatory regulator I\u03baB\u03b6: induction, regulation and physiological functions. Front. Immunol. 14, 1188253 (2023).","journal-title":"Front. Immunol."},{"key":"22034_CR86","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/s41467-022-28372-y","volume":"13","author":"N Abdelfattah","year":"2022","unstructured":"Abdelfattah, N. et al. Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target. Nat. Commun. 13, 767 (2022).","journal-title":"Nat. Commun."},{"key":"22034_CR87","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.3892\/ijo.2015.3159","volume":"47","author":"H Brennenstuhl","year":"2015","unstructured":"Brennenstuhl, H., Armento, A., Braczysnki, A. K., Mittelbronn, M. & Naumann, U. I\u03baB\u03b6, an atypical member of the inhibitor of nuclear factor kappa B family, is induced by \u03b3-irradiation in glioma cells, regulating cytokine secretion and associated with poor prognosis. Int. J. Oncol. 47, 1971\u20131980 (2015).","journal-title":"Int. J. Oncol."},{"key":"22034_CR88","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s12192-019-01044-5","volume":"24","author":"D Scieglinska","year":"2019","unstructured":"Scieglinska, D., Krawczyk, Z., Sojka, D. R. & Gogler-Pig\u0142owska, A. Heat shock proteins in the physiology and pathophysiology of epidermal keratinocytes. Cell Stress Chaperones 24, 1027\u20131044 (2019).","journal-title":"Cell Stress Chaperones"},{"key":"22034_CR89","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1055\/s-0043-1777761","volume":"86","author":"Z Wang","year":"2025","unstructured":"Wang, Z., Fang, Z., Gui, Y., Xi, B. & Xie, Z. Elevated HSPB1 expression is associated with a poor prognosis in glioblastoma multiforme patients. J. Neurol. Surg. A Cent. Eur. Neurosurg. 86, 17\u201329 (2025).","journal-title":"J. Neurol. Surg. A Cent. Eur. Neurosurg."},{"key":"22034_CR90","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1186\/s12885-015-1473-9","volume":"15","author":"M Gimenez","year":"2015","unstructured":"Gimenez, M. et al. Quantitative proteomic analysis shows differentially expressed HSPB1 in glioblastoma as a discriminating short from long survival factor and NOVA1 as a differentiation factor between low-grade astrocytoma and oligodendroglioma. BMC Cancer 15, 481 (2015).","journal-title":"BMC Cancer"},{"key":"22034_CR91","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1186\/s12885-023-10983-3","volume":"23","author":"Q Huo","year":"2023","unstructured":"Huo, Q., Wang, J. & Xie, N. High HSPB1 expression predicts poor clinical outcomes and correlates with breast cancer metastasis. BMC Cancer 23, 501 (2023).","journal-title":"BMC Cancer"},{"key":"22034_CR92","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s12192-014-0537-0","volume":"20","author":"GN Castro","year":"2015","unstructured":"Castro, G. N. et al. Effects of temozolomide (TMZ) on the expression and interaction of heat shock proteins (HSPs) and DNA repair proteins in human malignant glioma cells. Cell Stress Chaperones 20, 253\u2013265 (2015).","journal-title":"Cell Stress Chaperones"},{"key":"22034_CR93","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s12192-019-01004-z","volume":"24","author":"E \u00d6nay U\u00e7ar","year":"2019","unstructured":"\u00d6nay U\u00e7ar, E. & \u015eengelen, A. Resveratrol and siRNA in combination reduces Hsp27 expression and induces caspase-3 activity in human glioblastoma cells. Cell Stress Chaperones 24, 763\u2013775 (2019).","journal-title":"Cell Stress Chaperones"},{"key":"22034_CR94","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s12192-018-0896-z","volume":"23","author":"A \u015eengelen","year":"2018","unstructured":"\u015eengelen, A. & \u00d6nay-U\u00e7ar, E. Rosmarinic acid and siRNA combined therapy represses Hsp27 (HSPB1) expression and induces apoptosis in human glioma cells. Cell Stress Chaperones 23, 885\u2013896 (2018).","journal-title":"Cell Stress Chaperones"},{"key":"22034_CR95","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1210\/mend.11.11.9916","volume":"11","author":"W Porter","year":"1997","unstructured":"Porter, W., Saville, B., Hoivik, D. & Safe, S. Functional synergy between the transcription factor Sp1 and the estrogen receptor. Mol. Endocrinol. 11, 1569\u20131580 (1997).","journal-title":"Mol. Endocrinol."},{"key":"22034_CR96","doi-asserted-by":"publisher","first-page":"lqae019","DOI":"10.1093\/nargab\/lqae019","volume":"6","author":"A Prabahar","year":"2024","unstructured":"Prabahar, A. et al. Unraveling the complex relationship between mRNA and protein abundances: a machine learning-based approach for imputing protein levels from RNA-seq data. NAR Genom Bioinform 6, lqae019 (2024).","journal-title":"NAR Genom Bioinform"},{"key":"22034_CR97","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2018101323","volume":"38","author":"J Lorent","year":"2019","unstructured":"Lorent, J. et al. Translational offsetting as a mode of estrogen receptor \u03b1-dependent regulation of gene expression. EMBO J. 38, e101323 (2019).","journal-title":"EMBO J."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22034-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22034-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22034-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T01:02:44Z","timestamp":1762304564000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22034-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":97,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["22034"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-22034-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"9 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Insilico Medicine is a company developing an AI-based end-to-end integrated pipeline for drug discovery and development and engaged in aging and cancer research. AS, AV, KMA, AU, MK, AZ are affiliated with Insilico Medicine. SQ, HLR, and SSH each hold shares in Atossa Therapeutics, Inc. but declare no non-financial competing interests. HLR is lead independent director of Atossa Therapeutics, Inc.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38225"}}